


## LUF6000

## Chemical Properties

CAS No. :	890087-21-5
Formula:	C <sub>22</sub> H <sub>20</sub> Cl <sub>2</sub> N <sub>4</sub>
Molecular Weight:	411.33
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR).
Targets(IC50)	Others, Adenosine Receptor
In vitro	LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside antagonist MRS1220, into an agonist. LUF6000 exerted an Emax-enhancing effect at a concentration of 0.1 microM or higher and was shown to increase the Emax of Cl-IB-MECA and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA. A3 adenosine receptor LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists.

## Solubility Information

Solubility	DMSO: 14.29 mg/mL (34.74 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (2.43 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.4311 mL	12.1557 mL	24.3114 mL
5 mM	0.4862 mL	2.4311 mL	4.8623 mL
10 mM	0.2431 mL	1.2156 mL	2.4311 mL
50 mM	0.0486 mL	0.2431 mL	0.4862 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Gao ZG, Verzijl D, Zweemer A et al. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. *Biochem Pharmacol.* 2011 Sep 15;82(6):658-68. doi: 10.1016/j.bcp.2011.06.017.

Szentmiklósi AJ, Cseppento A, Harmati G, Nánási PP. Novel trends in the treatment of cardiovascular disorders: site- and event- selective adenosinergic drugs. *Curr Med Chem.* 2011;18(8):1164-87.

Heitman LH, Göblyös A, Zweemer AM, et al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. *J Med Chem.* 2009 Feb 26;52(4):926-31.

Gao ZG, Ye K, Göblyös A, et al. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. *BMC Pharmacol.* 2008 Dec 12;8:20.

Göblyös A, Gao ZG, Brussee J, et al. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. *J Med Chem.* 2006 Jun 1;49(11):3354-61.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481